Noemí Del Castillo

Prof. Dr. Noemí Del Castillo


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2022 in Veterinary Sciences
Verified
Journal Article
Open access
PDF file
CMClara Martín-Carrasco
Clara Martín-Carrasco
PDPablo Delgado-Bonet
Pablo Delgado-Bonet
BMBeatriz Davinia Tomeo Martín
Beatriz Davinia Tomeo Martín
JPJosep Pastor
Josep Pastor
CFClaudia de la Riva Fraga
Claudia de la Riva Fraga
APAna Judith Perisé-Barrios
Ana Judith Perisé-Barrios
The use of oncolytic viruses is an innovative approach to lyse tumor cells and induce antitumor immune responses. Eight dogs diagnosed with carcinoma/adenocarcinoma were intratumorally treated with ICOCAV15, an oncolytic canine adenovirus (CAV). To evaluate the treatment’s safety, a blood count, biochemistry, and coagulation test were performed before treatment and during follow-up. Immune populations were analyzed by flow cytometry. Anti-adenovirus antibodies were also determined. The immune infiltration, vascularization, and viral presence in the tumor were determined by CD3, CD4, CD20, CD31 and CAV by immunohistochemistry. All the dogs maintained a good quality of life during follow-up, and some had increased median survival time when compared with dogs treated with chemotherapy. No treatment-related adverse effects were detected. The Response Evaluation Criteria In Solid Tumors criteria were also assessed: two patients showed a partial response and the rest showed stable disease at various times during the study. ICOCAV15 was detected inside the tumor during follow-up, and antiviral antibodies were detected in all patients. Furthermore, the tumor-infiltrating immune cells increased after viral administration. Therefore, we suggest that intratumorally administered ICOCAV15 could represent as a new tool for the treatment of canine carcinoma because it is safe, well-tolerated by dogs, and shows promising results.

2 November 2025 in Veterinary Sciences
Verified
Journal Article
Open access
PDF file
NCNoemí Del Castillo
Noemí Del Castillo
MFManuel Fuertes-Recuero
Manuel Fuertes-Recuero
EAElisabetta De Angelis
Elisabetta De Angelis
CFClaudia de la Riva Fraga
Claudia de la Riva Fraga
CGCristina García
Cristina García
Gustavo Ortiz-DíezGustavo Ortiz-Díez
Gustavo Ortiz-Díez
This retrospective case series describes 21 dogs with stage II splenic haemangiosarcoma (HSA) and spontaneous haemoabdomen treated with splenectomy followed by a doxorubicin–cyclophosphamide protocol. Median overall survival was 92 days, with longer survival observed in dogs completing three or more chemotherapy cycles. The regimen was well tolerated, with low haematological and gastrointestinal toxicity. Maintenance metronomic chemotherapy was administered in a small subset, and it was associated with prolonged survival. While the sample size is modest, the homogeneous and clinically specific cohort provides hypothesis-generating observations on feasibility, tolerability, and time-aware associations that warrant cautious interpretation and prospective confirmation. No clinical or laboratory variable at diagnosis was independently associated with outcome. While limited by retrospective design and small sample size, this study provides focused data on a specific clinical presentation and supports the feasibility of structured adjuvant treatment in dogs with splenic HSA and haemoabdomen.